LUTRONIC Corporation
14
0
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
88.9%
+2.4% vs industry average
7%
1 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Lutronic PicoPlus Exploratory Clinical Trial
Role: lead
Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning
Role: lead
Safety and Efficacy Evaluation of the Mosaic Ultra Device
Role: lead
Lutronic Genius System for Neck Treatment
Role: lead
Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands
Role: lead
Histologic Evaluation of Tissue Following Lutronic System Exposure
Role: lead
The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation
Role: collaborator
Lutronic LaseMD for Treatment of Benign Pigmented Lesions
Role: lead
LaseMD System for the Treatment of Melasma
Role: lead
Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema
Role: lead
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
Role: lead
Lutronic Infini and LaseMD Systems in Combination Treatment
Role: lead
The Efficacy and Safety of the 1,414 nm Nd:YAG Laser System for Alleviating Back Pain in a Lumbar Disc Patient
Role: lead
Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm
Role: lead
All 14 trials loaded